Fas-Linked Retention Signal for Transduced Cell Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for adoptive immunotherapy, such as CAR-T cell therapy, face challenges in purifying transduced cells, addressing antigen heterogeneity, and preventing FasL-induced apoptosis, which affects the efficacy and safety of cancer treatment.
Innovation Solution
A method involving the transduction of cells with a vector co-expressing a nucleic acid sequence that inhibits Fas expression or activity, combined with FasL, to selectively eliminate untransduced cells and alloreactive T-cells, using FasL-mediated apoptosis for self-selection and cancer cell targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transduction efficiency is increased to improve product effectiveness, then the proportion of transduced cells increases, but purification complexity and manufacturing costs increase
Solution Approach 1:
The patent employs self-selection mechanisms where transduced cells automatically separate from untransduced cells through intrinsic properties. Specifically, transduced cells exhibit altered Fas expression levels or apoptotic sensitivity compared to untransduced cells, allowing spontaneous enrichment without external purification intervention. This self-service approach eliminates complex purification steps while maintaining high transduced cell proportions.
Solution Approach 2:
The invention exploits parameter changes in cell behavior following transduction. By modifying Fas expression levels or apoptotic response parameters through viral transduction, the patent creates detectable and selectable differences between transduced and untransduced cells. These parameter changes enable simple selection methods such as FasL treatment or flow cytometry-based sorting, dramatically reducing purification complexity.
2Reliability
If multiple vectors are used to ensure complete CAR expression, then all transduced cells express CAR polypeptide, but the complexity of ensuring complete transduction increases
Solution Approach 1:
The patent implements feedback mechanisms where the transduction process itself provides selection pressure. By linking CAR expression to altered Fas sensitivity or expression levels, the system creates a feedback loop where only successfully transduced cells survive selective pressures. This automatic feedback eliminates the need for complex multi-vector systems while ensuring complete CAR expression in the final product.
Solution Approach 2:
The invention performs preliminary selection actions during or immediately after transduction. By applying FasL treatment or other selective pressures right after transduction, the patent pre-selects for completely transduced cells before administration. This preliminary action ensures CAR expression completeness without requiring complex multi-vector transduction protocols.
3Manufacturing precision
If flow cytometry or magnetic bead purification is used to increase transduced cell proportion, then product purity increases, but manufacturing costs and stress on cells increase
Solution Approach 1:
The patent replaces active purification processes with passive self-selection mechanisms. Transduced cells naturally separate from untransduced cells through differential Fas expression or apoptotic sensitivity, eliminating the need for expensive flow cytometry or magnetic bead purification. This self-service approach maintains high product purity while dramatically reducing manufacturing costs and cellular stress.
4Reliability
If cells are purified post-transduction to increase transduced cell proportion, then product effectiveness increases, but cell exhaustion and differentiation state may be affected
Solution Approach 1:
The patent employs gentle self-selection mechanisms that avoid the mechanical and chemical stresses of traditional purification methods. By using FasL-mediated selection or apoptotic sensitivity differences, the patent enriches for transduced cells without subjecting them to the exhaustion and differentiation pressures caused by flow cytometry or magnetic bead purification. This maintains cell composition stability while achieving high product effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the purity and efficacy of transduced cell products, improves cell persistence in the tumor microenvironment, and effectively targets cancer cells, including antigen-negative ones, while reducing the risk of graft-versus-host disease.
Implementation Method 1
exposing the cells from (a) to FasL. Untransduced cells are thereby eliminated by apoptosis
Data Source
AI summary
The present invention provides a method for selecting for cells transduced to express a nucleic acid sequence of interest (NOI), which comprises the following steps: (a) transducing a population of cells with a vector co-expressing the NOI and a nucleic acid sequence which inhibits Fas expression or activity in the cell; (b) exposing the cells from (a) to FasL such that untransduced cells are eliminated by apoptosis. The present invention also provides a molecule which comprises a Fas-binding domain linked to an intracellular retention signal which may be used in such a method to inhibit Fas expression.